HBeAg阳性慢性HBV 感染分期和治疗新进展

doi:10.3969/j.issn.1672-5069.2023.05.003

实用肝脏病杂志 ›› 2023, Vol. 26 ›› Issue (5): 615-617.doi: 10.3969/j.issn.1672-5069.2023.05.003

HBeAg阳性慢性HBV 感染分期和治疗新进展

彭真, 宁会彬, 李宽, 尚佳

450000 郑州市河南省人民医院感染病科

收稿日期:2023-07-12 出版日期:2023-09-10 发布日期:2023-09-13
通讯作者: 尚佳,E-mail: shangjia666@126.com
作者简介:彭真,女,41岁,医学博士,副主任医师。主要从事肝病和不明原因发热的诊断与治疗学研究。E-mail: 18203685921@163.com

Infection staging and antiviral strategy in individuals with chronic serum HBeAg-positive hepatitis B viral infection

Peng Zhen, Ning Huibin, Li Kuan, et al

Department of Infectious diseases, Provincial People's Hospital, Zhengzhou University, Zhengzhou 450000, Henan Province, China

Received:2023-07-12 Online:2023-09-10 Published:2023-09-13

摘要/Abstract

关键词: 乙型肝炎, 感染分期, 治疗

Key words: Hepatitis B, Infection stage, Therapy

彭真, 宁会彬, 李宽, 尚佳. HBeAg阳性慢性HBV 感染分期和治疗新进展[J]. 实用肝脏病杂志, 2023, 26(5): 615-617.

Peng Zhen, Ning Huibin, Li Kuan, et al. Infection staging and antiviral strategy in individuals with chronic serum HBeAg-positive hepatitis B viral infection[J]. Journal of Practical Hepatology, 2023, 26(5): 615-617.

参考文献

[1] 中华医学会肝病学分会. 扩大慢性乙型肝炎抗病毒治疗的专家意见. 中华肝脏病杂志,2022,30(2):131-136.
[2] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2022年版).实用肝脏病杂志,2023,26(3)S18-39.
[3] Likhitsup A, Lok AS. Understanding the natural history of hepatitis B virus infection and the new definitions of cure and the endpoints of clinical trials. Clin Liver Dis, 2019,23(3):401-416.
[4] Yim HJ, Kim JH, Park JY, et al. Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. Clin Mol Hepatol, 2020,26(4):411-429.
[5] Hui CK, Leung N, Yuen ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology, 2007,46(2):395-401.
[6] EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol, 2017,67(2):370-398.
[7] Huang DQ, Li X, Le MH, et al. Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase. Clin Gastroenterol Hepatol, 2022,20(8):1803-1812,e5.
[8] Spradling PR, Xing J, Rupp LB, et al. Distribution of disease phase, treatment prescription and severe liver disease among 1598 patients with chronic hepatitis B in the Chronic Hepatitis Cohort Study, 2006-2013. Aliment Pharmacol Ther, 2016,44(10):1080-1089.
[9] 刘春云, 常丽仙, 李俊义,等. HBV感染免疫耐受期肝组织炎症和纤维化的影响因素分析. 临床肝胆病杂志,2022,38(9):2005-2009.
[10] 曾湛, 高媛娇, 毕潇月,等. HBsAg水平对ALT正常的HBeAg阳性慢性HBV感染者肝脏炎症发生的预测价值. 临床肝胆病杂志,2022,38(5):1030-1034.
[11] Lee WM. Hepatitis B virus infection. N Engl J Med, 1997,337(24):1733-1745.
[12] 辛杰晶, 东冰, 任丹丹,等. ALT正常HBeAg阳性慢性HBV感染者免疫耐受期与不确定期临床特征. 中华临床感染病杂志,2022,15(4):285-290.
[13] Lee HA, Kim SU, Seo YS, et al. Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis. Hepatol Commun, 2023,7(2):e0011.
[14] Lee HW, Chon YE, Kim BK, et al. Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. Eur J Intern Med, 2021,84:68-73.
[15] Seong G, Sinn DH, Kang W, et al. Age and fibrosis index for the prediction of hepatocellular carcinoma risk in patients with high hepatitis B virus DNA but normal alanine aminotransferase. Eur J Gastroenterol Hepatol, 2022,34(1):69-75.
[16] Kim DY. History and future of hepatitis B virus control in South Korea. Clin Mol Hepatol, 2021,27(4):620-622.
[17] Lee HA, Lee HW, Kim IH, et al. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. Aliment Pharmacol Ther, 2020,52(1):196-204.
[18] Yoo JJ, Park SY, Moon JE, et al. Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase. Clin Mol Hepatol, 2023,29(2):482-495.
[19] Yapali S, Talaat N, Fontana RJ, et al. Outcomes of patients with chronic hepatitis B who do not meet criteria for antiviral treatment at presentation. Clin Gastroenterol Hepatol, 2015,13(1):193-201,e1.
[20] Ning Q, Han M, Sun Y, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol, 2014,61(4):777-784.
[21] Wang Q, Li H, Ding D, et al. Upgrade combination response is limited by prolonged nucelos(t)ide analogue therapy in HBeAg-positive chronic hepatitis B: A real-life study. J Clin Transl Hepatol, 2018,6(1):11-17.
[22] 专家意见编写组. 慢性乙型肝炎抗病毒治疗药物临床试验技术指导原则专家意见. 中华肝脏病杂志,2022,30(5):493-504.
[23] Fanning GC, Zoulim F, Hou J, et al. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov, 2019,18(11):827-844.

HBeAg阳性慢性HBV 感染分期和治疗新进展

Infection staging and antiviral strategy in individuals with chronic serum HBeAg-positive hepatitis B viral infection

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	盛秋菊, 窦晓光. 慢性HBV感染不同疾病状态治疗策略选择与获益评价[J]. 实用肝脏病杂志, 2023, 26(5): 609-611.
[2]	张丹, 丁洋. 慢性乙型肝炎患者病毒载量与疾病状态和治疗策略选择^*[J]. 实用肝脏病杂志, 2023, 26(5): 612-614.
[3]	吴育龙, 庄见齐, 刘志成, 马侠槟. 核苷(酸)类似物治疗慢性乙型肝炎患者血清HBV pgRNA变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(5): 622-625.
[4]	王一卓, 张崴琪, 李红. 聚乙二醇干扰素α-2a治疗HBeAg阳性慢性乙型肝炎患者3年随访研究[J]. 实用肝脏病杂志, 2023, 26(5): 626-629.
[5]	郝岸华, 杜忠彩, 周林, 马磊. 慢性乙型肝炎患者肝脏硬度检测和S指数变化及评估肝纤维化程度应用价值探讨^*[J]. 实用肝脏病杂志, 2023, 26(5): 630-633.
[6]	刘爱华, 符建, 陈小红. 瞬时超声弹性成像联合GGT/PLT比值预测慢性乙型肝炎患者肝纤维化价值研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 634-637.
[7]	李亚玲, 杨发成, 蒋亚西. 直接抗病毒药物治疗慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 638-641.
[8]	蔡涛, 魏玮, 王欣雯, 王玥坤, 秦军, 蓝晓红. 直接抗病毒药物治疗慢性终末期肾病合并慢性丙型肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 642-645.
[9]	罗良德, 苏建明, 任成果, 申红. 复方甘草酸苷联合非诺贝特治疗代谢相关性脂肪性肝病患者疗效及其对脂代谢的影响^*[J]. 实用肝脏病杂志, 2023, 26(5): 650-653.
[10]	莫俊俏, 林景, 羊莉. 水飞蓟宾胶囊联合多烯磷脂酰胆碱治疗抗结核药物所致药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 666-669.
[11]	武向慧, 李龙虎, 景斐华, 武鹏. 经导管动脉化疗栓塞联合射频消融治疗肝细胞癌患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 702-705.
[12]	陈长广, 肖荣, 王俊. DEB-TACE序贯射频消融治疗原发性肝癌患者效果研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 706-709.
[13]	张树庚, 张少博, 朱泽斌, 栗雪峰, 蔡伟, 郭亚飞, 刘连新. Clavien-Dindo分级系统分析不同供肝类型肝移植患者术后早期并发症发生率比较研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 738-741.
[14]	叶超荣, 张涛, 吴永军, 利民. LCBDE与ERCP术治疗胆总管结石患者效果研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 742-745.
[15]	宋巍, 李智德, 李玉鹏, 陈雄. 吲哚菁绿荧光显像指导腹腔镜胆囊切除术治疗胆囊良性疾病患者效果研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 746-749.